Global Markets for Treatments for Syndromes of Dementia and Movement Disorders
The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.
SCOPE OF THE STUDY
The scope of this study encompasses the neurodegenerative disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and Mexico.
ABOUT THE AUTHOR
The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this study is Shalini S. Dewan, who holds a master’s degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.
Some of her other reports with BCC include Reagents for Chromatography; Spectroscopy—An Enduring Market; Advanced Drug Delivery Systems—Technologies and Global Markets; Orthopedic Drugs, Implants and Devices—Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry—The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging—Global Markets; Chiral Technology—Global Markets; Autacoids and Related Drugs—Technologies and Global Markets; Contraceptives—Technologies and Global Markets; Liver Disease Treatments—The Global Market; Hormone Replacement Therapies and Other Hormone Therapies—Global Markets; Cardiovascular Medicine—Diagnostics, Drugs and Devices; and Cancer Therapies − Technologies and Global Markets.
The lead consultant on this project is Ms. Ruma Chakravarty, who holds a master’s degree in biophysics. She has tremendous experience in market research, quality, process improvement and lean and six sigma concepts.